Tests:Alpha Fetoprotein, Tumor Marker: Difference between revisions
Tests:Alpha Fetoprotein, Tumor Marker
corrected sample types etc |
|||
| (One intermediate revision by one other user not shown) | |||
| Line 36: | Line 36: | ||
|- | |- | ||
|Acceptable | |Acceptable | ||
|tube | |Plain Yellow-top or <span style="background:#e30022"> Red-Top </span> tube | ||
|- | |- | ||
|Unacceptable | |Unacceptable | ||
| Line 87: | Line 87: | ||
For the serial monitoring of tumours, tumour markers should be tested in the same laboratory. | For the serial monitoring of tumours, tumour markers should be tested in the same laboratory. | ||
|} | |} | ||
{{DocMeta | |||
| owner = Crossley1 | |||
| review_ping = | |||
}} | |||
Latest revision as of 19:51, 14 September 2026
Overview | |
|---|---|
| Department | Biochemistry |
| Test Code | TAFP |
| Synonyms | Tumour Marker (AFP)
AFP (tumour marker) |
| Availability | Performed Mon-Fri. Available out of hours except weekends and public holidays |
| Turnaround Time | 1 hour to 3 days. |
| Stability – Add test | 24 hours |
Specimen Requirements | |
| Specimen | Serum |
| Preferred | Plain Yellow-top or Red-Top tube |
| Acceptable | Plain Yellow-top or Red-Top tube |
| Unacceptable | Plasma samples |
| Paediatric Requirements | 0.5 mL paediatric Red-Top |
Aliquot Requirements | |
| Sample | Serum |
| Preferred Volume | >500 µL |
| Minimum Volume | 200 µL |
| Aliquot Transportation | |
| == Clinical Information == | |
| Reference Intervals | 0 - 16 µg/L (non-pregnant)
See comment |
| Test Method | Abbott Alinity CI analyser , Abbott Reagent. |
| Advanced Notice | Not required |
| Patient Preparation | Not required |
Comments | |
| This test is useful as a tumour marker and as a safe and effective supplement to the management of patients undergoing treatment for non-seminomatous testicular cancer and
certain germ cell cancers, or for patients being monitored after therapy is complete. The test is NOT a screening test for cancer. The test is NOT intended as a screen for neural tube defects. For the serial monitoring of tumours, tumour markers should be tested in the same laboratory. | |
| Owner | Clair Crossley (Crossley1) |
|---|---|
| Last reviewed | 14.09.2026 |
| Next review | 14.09.2027 (OK) |